$KOSS

Executive VP at Koss (NASDAQ: KOSS) receives 100,000 stock options

Koss Corp's Executive Vice President, Michael J. Koss Jr., has been granted 100,000 stock options at an exercise price of $4.73 per share. These options will vest in four equal annual installments starting May 6, 2027, and expire on May 6, 2031. This grant is part of his compensation, and post-filing, he holds 26,000 direct shares and 12 indirect shares through an ESOP, in addition to the new options.

Original reporting
Published May 9, 2026, 3:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 9, 2026, 3:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$KOSS
Bullish
medium confidence
Mentioned
$KOSS
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$KOSSBullishMed
01

Why it matters

The insider stock options grant could signal management's confidence in upcoming product launches or strategic initiatives, potentially leading to positive market reactions.

02

Market read

While the insider activity is noteworthy, it is one of many factors influencing Koss stock; traders should consider it within the broader context of company fundamentals and market conditions.

03

What to watch

Broader market conditions, recent earnings reports, and industry trends should be considered before making trading decisions.

Relevance 6/10Timing: Immediate, as the news is recent and pertains to upcoming vesting dates.

Background

Koss Corporation has been operating in a competitive consumer electronics market, with recent efforts to innovate and expand product lines.

Company-level read

Ticker impact

$KOSSBullishMedium confidence
Context

The news pertains directly to Koss Corporation, indicating insider activity that could influence stock price.

Expected impact

Moderate upward movement in the short term, contingent on market perception.

Evidence & confidence

Insider option grants are often interpreted as a sign of management's confidence, but the actual impact depends on broader market conditions and investor sentiment.

Market effects

Potential positive influence on the technology and consumer electronics sectors if similar insider activities are observed.

Limited, as Koss is a regional player with a focus on the US market.

Negligible, given the company's size and market scope.

Counterpoint

Insider option grants may be a routine part of compensation and not indicative of future stock performance; market may interpret this as management hedging or aligning interests without substantial operational change.

Key entities

  • Koss Corporation

    A manufacturer of headphones and audio products listed on NASDAQ.

  • Michael J. Koss Jr.

    Executive Vice President of Koss Corporation, involved in strategic decision-making.

Related articles

$KOSSMed

Koss Corporation Releases Fourth Quarter and Full Year Results

KOSS CORP (KOSS) filed an SEC Form 8-K — Results of Operations and Financial Condition.  FOR IMMEDIATE RELEASE CONTACT: Michael J. Koss August 2 7 , 202 6 Chairman & CEO (414) 964-5000 mjkoss@koss.com  Koss Corporation Releases Fourth Quarter and Full Year Results Milwaukee, Wisconsin: Koss Corporation (NASDAQ: KOSS) (the “Company”) , the U.S. based high-fidelity

$LLYMed

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Eli Lilly (LLY) presented Phase 1 data for its investigational drug sofetabart mipitecan (Sofe-M) plus bevacizumab, showing a 79% objective response rate and 100% disease control rate in platinum-sensitive ovarian cancer. The study included 33 patients, with responses consistent across FRα expression levels and prior PARP inhibitor exposure. Sofe-M is being studied in multiple Phase 3 trials under the FRAmework-01 program.

$IMTXMedAI 8/10

One-time cell therapy at clinically relevant doses had a 55% confirmed response rate in 20 gynecologic cancer patients.

Immatics N.V. (IMTX) reported updated clinical trial data for IMA402 and IMA203CD8. IMA402 showed a 32% cORR and 91% 1-year OS in advanced melanoma patients. IMA203CD8 achieved a 55% cORR in gynecologic cancers with a median DOR of 8.4 months. Both treatments demonstrated favorable safety profiles. The data were presented at the ESMO 2026 meeting.

$AIBLow

BlockchAIn Digital Infrastructure Unveils $1B+ Nebius Data Center Lease Strategy

BlockchAIn Digital Infrastructure (AIB) announced a $1B+ lease strategy for its first data center development, anchored by Nebius. The 12-year lease includes 50 MW IT load, with initial construction expected in 10 months. The company plans to use customer prepayments and project-level debt for funding. AIB also has additional projects in Texas and other states, targeting 200-300 MW under contract by year-end.